title: Management of Mucositis During Chemotherapy: From Pathophysiology to Pragmatic Therapeutics.
abstract: Chemotherapy-induced mucositis is a common condition caused by the breakdown of the mucosal barrier. Symptoms can include pain, vomiting and diarrhoea, which can often necessitate chemotherapy treatment breaks or dose reductions, thus compromising survival outcomes. Despite the significant impact of mucositis, there are currently limited clinically effective pharmacological therapies for the pathology. New emerging areas of research have been proposed to play key roles in the development of mucositis, providing rationale for potential new therapeutics for the prevention, treatment or management of chemotherapy-induced mucositis. This review aims to address these new areas of research and to comment on the therapeutics arising from them.
authors.affiliation: School of Medicine, University of Adelaide, North Terrace, Adelaide, SA, 5005, Australia. ysabella.vansebille@adelaide.edu.au.
authors.forename: Ysabella Z A
authors.initials: YZ
authors.lastname: Van Sebille
authors.affiliation: School of Medicine, University of Adelaide, North Terrace, Adelaide, SA, 5005, Australia.
authors.forename: Romany
authors.initials: R
authors.lastname: Stansborough
authors.affiliation: School of Medicine, University of Adelaide, North Terrace, Adelaide, SA, 5005, Australia.
authors.forename: Hannah R
authors.initials: HR
authors.lastname: Wardill
authors.affiliation: School of Medicine, University of Adelaide, North Terrace, Adelaide, SA, 5005, Australia.
authors.forename: Emma
authors.initials: E
authors.lastname: Bateman
authors.affiliation: School of Medicine, University of Adelaide, North Terrace, Adelaide, SA, 5005, Australia.
authors.forename: Rachel J
authors.initials: RJ
authors.lastname: Gibson
authors.affiliation: School of Medicine, University of Adelaide, North Terrace, Adelaide, SA, 5005, Australia.
authors.forename: Dorothy M
authors.initials: DM
authors.lastname: Keefe
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects*; D004338:Drug Combinations; D051523:Fibroblast Growth Factor 7 / Q000627:therapeutic use; D041981:Gastrointestinal Tract / Q000187:drug effects / Q000473:pathology*; D006801:Humans; D006820:Hyaluronic Acid / Q000627:therapeutic use; D007413:Intestinal Mucosa / Q000187:drug effects / Q000473:pathology*; D052016:Mucositis / Q000139:chemically induced / Q000628:therapy*; D011205:Povidone / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D019936:Probiotics / Q000627:therapeutic use; D019699:Thrombospondins / Q000627:therapeutic use; D019287:Zinc Sulfate / Q000627:therapeutic use; D000098907:R-Spondins
chemical_list: D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000970:Antineoplastic Agents; D004338:Drug Combinations; D051523:Fibroblast Growth Factor 7; D006820:Hyaluronic Acid; D011205:Povidone; D019699:Thrombospondins; D019287:Zinc Sulfate; C439265:Gelclair; C503243:RSPO1 protein, human; D000098907:R-Spondins
keywords: Analgesics; Antimicrobials; Antioxidants; Benzydamine hydrochloride (HCl); Cancer side effects; Chemotherapy-induced gut toxicity; Coating agents; Mucositis; Mucositis treatment; Palifermin; Probiotics; R-spondin1; Toxicity; Zinc sulphate